A client is beginning aldesleukin (Proleukin) therapy for ...

[cdr_15]

A client is beginning aldesleukin (Proleukin) therapy for advanced renal carcinoma. The nurse should monitor the client for:
 
  1. capillary leak syndrome.
  2. hypertension.
  3. hyperglycemia.
  4. hyperuricemia.

Question 2

What is the expected outcome for the client receiving filgrastim (Neupogen)?
 
  1. Increased white cell count
  2. Reduction in tumor size
  3. Reduction in paresthesia
  4. Increased platelet count

[billybob123]

Answer to Question 1

Correct Answer: 1
Rationale 1: Capillary leak syndrome is a significant side effect of aldesleukin and can be fatal.
Rationale 2: Aldesleukin does not cause hypertension.
Rationale 3: Hyperglycemia is not a side effect of aldesleukin.
Rationale 4: Hyperuricemia is not a side effect of aldesleukin.
Global Rationale: Aldesleukin is a toxic drug that has the potential to cause serious adverse effects in virtually any organ system. Many of the adverse effects are caused by capillary leak syndrome, a serious condition in which plasma proteins and other substances leave the blood and enter the interstitial spaces because of porous capillaries. If not monitored carefully, capillary leak syndrome can result in death. The drug is not associated with hypertension, hyperglycemia, or hyperuricemia.

Answer to Question 2

Correct Answer: 1
Rationale 1: Filgrastim increases white cell counts.
Rationale 2: Filgrastim has no effect on tumor size.
Rationale 3: Filgrastim does not reduce paresthesia.
Rationale 4: Filgrastim has no effect on platelet counts.
Global Rationale: Filgastim is a colony-stimulating factor which stimulates the production of granulocytes. It has no effect on tumor size, does not reduce paresthesia, and has no effect on platelet counts.

[cdr_15]

Thank you!

[billybob123]

Always glad to help...